Description

Description

According to WHO’s data in 2005, glaucoma is the second leading cause of blindness after cataracts and the most common irreversible cause of blindness in the world. There are 70 million glaucoma patients worldwide, and it is estimated that the number will reach 80 million in 2020. Blindness caused by glaucoma accounts for 50% of global blindness. China has the largest number (over 24 million) of glaucoma patients in the world, and this number is growing at a rate of more than 1.5 million per year.

Latanoprost is the first FDA approved prostaglandin for intraocular pressure reduction. In 1999, China began importing Latanoprost as a first-line drug in the clinical treatment of glaucoma. In 2004, Latanoprost eye drops developed by Lunan Better were approved for sale, followed by the products of other domestic manufacturers. And there is a continuous rise in the market share of domestic manufacturers. In 2017, Pfizer had the largest market share by sales value, about 39%, a figure that has been declining in recent years.

According to CRI, Latanoprost has been growing since it entered China, with its sales value exceeding CNY 40 million in 2017. With an ageing population, the incidence of glaucoma is increasing year by year in China. In clinical practice, glaucoma cannot be well treated through operations as cataracts. Therefore, there is a promising market of conservative medications and post-operative medications, and thus a high demand for Latanoprost in China.

About

CRI provides customized industry research services for initial public offerings, corporate mergers and acquisitions, business development, market launch and financingfor clients varying from private companies to the government entities.